Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

POC INSTRUMENT - Proof of concept by Campagnia di San Paolo

2023
3VS: Prototyping and validation of a vesicular nanotechnological device for gene therapy alternative to viral vectors. This project was based on the patent “Method for obtaining concentrated populations of extracellular vesicles (EVs) washed of physiopathological load thereof”, WO2023/073609A1. The aim of the project was the encapsulation of a plasmid DNA inside lymphocytes-derived EVs, osmotically lysed using the method described in the patent. The efficacy and safety of this new vesicular viral vector substitute was compared with more traditional methods of gene transfer such as non-liposomal lipids and lentiviral vectors for the treatment of multiple myeloma.
FRAMEWORK
Campagnia di San Paolo
PARTNERS
Molecular Biology Center (MBC) of University of Turin, CNR of Turin

other projects

We firmly believe that one of the Group’s strengths lies in the transdisciplinary approach that stems from active collaboration between experts from different fields, crucial for achieving results in both research and technological transfer.
RESEARCH ACTIVITIES